← All trials
NCT03757338
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2015
- Primary completion
- Jan 26, 2016
- Completion date
- Jan 26, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 33
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Asofarma de México S.A de C.V.Lead sponsor
- Zenith TechnologiesOverall official - principal investigator
- Zenith TechnologiesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.